GLR1059 / Gan & Lee Pharma - LARVOL DELTA

GLR1059, next-generation nectin-4-targeted ADC with a novel mechanism-of-action payload, demonstrated significantly potent anti-tumor efficacy and reduced toxicity in preclinical evaluation (AACR 2025) - "Enfortumab Vedotin (EV) is the first approved nectin-4 antibody-drug conjugate (ADC) with MMAE as its payload for the treatment of urothelial carcinoma (UC). Preclinical data show that GLR1059 has the potential to achieve better efficacy and safety, and the different drug mechanisms provide new options to overcome drug resistance of current nectin-4 ADCs."

Preclinical • Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • NECTIN1 • NECTIN2 • NECTIN4